The American Conference Institute 2011 Clinical Trials survey results.

The statistics show that the clinical trials industry is booming, but public scrutiny of clinical trials sponsors and the potential for government enforcement is at an all time high. Inside you'll find what your peers are thinking and what may lie ahead for the clinical trials industry.

In response to the complexity facing the clinical trials industry in this tumultuous climate, ACI's 13th Advanced Forum on Managing Legal Risks in Structuring and Conducting Clinical Trials in the U.S. and Abroad provides a forum for all the key stakeholders- current and former government enforcers, top in-house counsel from pharmaceutical and medical device companies, hospitals and research institutions, and leading industry practitioners- to come together and share insights and practical tips you can implement now in order to structure a compliant clinical trials program. In this time of stepped-up enforcement by regulatory agencies and the Department of Justice (DOJ), companies must be vigilant about protecting human subjects and data validity, especially in jurisdictions where there is less regulation. It is more difficult than ever before to develop a strategic clinical trials program that maximizes data integrity and minimizes exposure to risk, and yet is also more critical to do so, in the face of the major uncertainty the clinical trials industry faces both domestically and internationally.

Clinical trial agreements simply must comply with good clinical practices, or companies can face audits leading to staggering civil penalties and even individual criminal punishment for any wrongdoers who do not abide by the rules. Hear from the experts who have already put established tactical plans for implementing large-scale clinical trials in place, and hear from the current and former enforcers who can help troubleshoot problem areas within clinical trials compliance. More is at stake than record-breaking fines and criminal and civil liability: successful clinical trials are crucial to a company's pipeline and market share. By teaching how to further develop good clinical practices, this conference will help you protect and increase revenue in this volatile economic climate.

Which of the following potential consequences of noncompliance in structuring and conducting clinical trials do you most fear?



In light of the FDA's stepped-up enforcement priorities in the context of clinical trials, are you more concerned with the specter of domestic audits or international audits?



The most challenging aspect in structuring and conducting international clinical trials is:



Three years post-enactment, I find FDAAA's disclosure requirements challenging to implement.



I would like to learn more about using the following social media platforms for patient recruitment:



What markets do you consider most attractive for clinical trial studies in the next six to twelve months?



Click on the logo above to follow the American Conference Institute on Twitter